➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,159,683

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,159,683 protect, and when does it expire?

Patent 10,159,683 protects DEXYCU KIT and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 10,159,683
Title:Use of sustained release dexamethasone in post-cataract surgery inflammation
Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), White; William S. (Birmingham, AL), Hu; Mae W. (Los Altos Hills, CA), Huang; Glenn T. (Fremont, CA), Karasina; Faina (Mountain View, CA)
Assignee: ICON BIOSCIENCE, INC. (Watertown, MA)
Application Number:16/018,931
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Device; Dosage form;

Drugs Protected by US Patent 10,159,683

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,159,683

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014268434   Start Trial
Canada 2913336   Start Trial
China 105407896   Start Trial
China 110339153   Start Trial
European Patent Office 3003318   Start Trial
Japan 2016526039   Start Trial
Japan 6530744   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.